Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on Omnicell (OMCL) to $40 from $49 and keeps an Equal Weight rating on the shares. The firm continues to see risks to Product revenue estimates in 2025 and elevated risks from health systems’ PnL.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL:
Questions or Comments about the article? Write to editor@tipranks.com